Navigation Links
Reportlinker Adds Global Pulmonary Drug Delivery Technologies industry
Date:5/17/2010

NEW YORK, May 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pulmonary Drug Delivery Technologies industry

http://www.reportlinker.com/p0197151/Global-Pulmonary-Drug-Delivery-Technologies-industry.html

This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in US$ Million by the following Product Segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of the World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 61 companies including many key and niche players such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes, Inc., Aradigm Corporation, AstraZeneca Plc, Baxter International Inc., Chiesi Farmaceutici SpA, Consort Medical Plc, Dey Pharma L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, NovartiS AG, Oriel Therapeutics, Inc., Sepracor, Inc., SkyePharma Plc, Valois S.A.S, and Vectura Group Plc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

PULMONARY DRUG DELIVERY TECHNOLOGIES MCP-1244

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Metered Dose Inhalers (MDIs) I-3

Dry Powder Inhalers (DPIs) I-4

Others I-4

Nebulizers I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Drug Delivery Technologies: A Primer II-1

Table 1: Worldwide Drug Delivery Market (2007): Percentage

Share Breakdown of Revenue by Technology Segment (includes

corresponding Graph/Chart) II-1

Drug Delivery Technologies Turns Critically Important to

Pharma Majors II-2

The Need for Novel Drug Delivery Technologies From A

Financial Standpoint II-2

Pulmonary Drug Delivery: A Preferred, Non-Invasive Drug

Administration Route II-3

Market Fundamentals: A Current Review II-3

Respiratory Disorders: A Large & Mature Therapeutic Category II-4

Widely Prescribed Inhalation Drugs for Asthma & COPD II-5

Inhaler Devices: An Integral Part of Pulmonary Drug Delivery II-5

Pulmonary Delivery of Systemic Drugs: A Future Growth Area II-5

Delivering Macromolecules Through the Lungs: A Current Focus

Area II-6

Innovations in Inhalation Aerosols II-7

Current Drugs in Pipeline: A Review II-8

Inhaled Drugs in Pipeline as of the Year 2008 & 2009 II-8

Noteworthy Trends & Issues II-11

Nanotechnology Makes its Presence Felt in Inhaled Drugs II-11

Innovation in Inhaler Devices: A Key Differentiating Factor II-12

Innovation is the Name of the Game in the Nebulizer Segment II-12

Nebulizers for Pediatric Care: Need of the Hour II-13

CFC Propellants Give Way to HFA II-14

Chinks in MDI's Armor Work in Favor of DPI Market II-14

Potential Challenges for DPI Market II-14

Combination Therapy: An Effective Strategy in Optimum

Disease Management II-15

2. PRODUCT OVERVIEW II-16

Definition of Pulmonary Drug Delivery System II-16

Benefits of Pulmonary Drug Delivery Systems II-16

Therapeutic Benefits II-17

Titration by Therapy II-17

Titration by Patient II-17

Dose Reproducibility II-17

High Bioavailability II-17

Other Key Advantages II-18

Pulmonary Drug Delivery Devices II-18

An Overview of Key Features of Popular Inhalation Devices II-18

Inhalers II-18

Metered Dose Inhalers (MDIs) II-18

Working Principle of an MDI II-19

CFC-Propellant based MDIs II-20

Ban on CFCs II-20

Use of Spacers in MDIs II-20

Benefits of Spacers II-21

Pros & Cons II-21

Advantages II-21

Unique Benefits of pMDIs II-21

Limitations II-21

Issues II-22

MDIs & Future II-22

Dry Powder Inhalers (DPIs) II-22

Inspiratory Flow Rate in DPIs II-23

Working Principle of DPIs II-23

Deaggregation in Dry Powder Inhalers (DPIs) II-23

Types of DPIs II-24

Passive DPI II-24

Active DPI II-24

Single-dose DPIs II-24

Multi-dose DPIs II-24

Other Types II-24

Benefits of DPIs II-25

Limitations II-25

Issues II-25

In a nutshell II-26

Comparison with MDIs II-26

Nebulizers II-27

Working Principle of a Nebulizer II-27

Use of UDMs in Nebulizers II-28

Types of Nebulizers II-28

Ultrasonic Nebulizers II-28

Gray Areas II-28

Benefits II-29

Limitations II-29

Pneumatic Nebulizers II-29

Breath-Actuated Nebulizers II-29

Continuous Nebulization II-30

Active Venturi Nebulizers II-30

New Designs for Improved Nebulizer Performance II-30

Limitations of Nebulizers II-30

Factors Influencing Clinical Effectiveness of Inhalation Device II-31

Device Factors II-31

Patient Factors II-31

Drug Factors II-31

3. AN OVERVIEW OF PULMONARY CONDITIONS AND THERAPIES II-32

The Respiratory System II-32

Pulmonary Drug Delivery - An Overview II-32

Asthma and COPD - Major Respiratory Disease Conditions II-32

Asthma: Primary Respiratory Syndrome II-32

Trigger Factors II-33

Magnitude of Disease II-33

Chronic Obstructive Pulmonary Disease II-34

Magnitude of Disease II-34

Treatment of Asthma and COPD II-34

Methods of Drug Delivery through Pulmonary Route II-34

Aerosols Systems II-35

Intratracheal Inhalation II-35

Insufflation II-35

Pulmonary Delivery Approaches II-35

Controlled Release II-36

Drug Medications for Treating Asthma and COPD II-36

Bronchodilators (Acute Reliever Drugs) II-36

Categories of Bronchodilators II-37

Short acting beta-agonists II-37

Long acting beta-agonists II-37

Anti-cholinergics II-38

Methylxanthines II-39

Combination Bronchodilators II-40

Available Inhaled Locally Acting Drugs II-40

Anti-Inflammatory Medication (Controllers or Preventers) II-40

Corticosteroids II-41

Inhaled Corticosteroids in Asthma II-41

Inhaled Corticosteroids in COPD II-42

Anti-Leukotrienes II-42

Innovative Therapeutic Approaches II-42

Combination Therapeutics II-43

4. PRODUCT INNOVATIONS/INTRODUCTIONS II-44

Pearl Therapeutics Announces Phase II Trials of

Glycopyrrolate Inhalation Aerosol in COPD II-44

PARI Receives Patent for Vortex Holding Chamber II-44

Schering-Plough Obtains Approval for Asmanex in Japan II-44

SkyePharma Inc Receives FDA Communication on Flutiform II-44

Almirall Announces Positive Results of Phase III Eklira II-45

MicroDose Therapeutx Initiates Phase 1 Study with Inhaled

Atropine II-45

PARI Pharma Announces Successful Phase Ib Results for Inhaled

L-CsA II-45

PARI Respiratory Launches PEP S II-46

3M Drug Delivery Systems Rolls Out 3M Conix DPI, 3M Taper DPI II-46

Akela Pharma Achieves Third Milestone in Fentanyl TAIFUN®

Phase III Study II-46

Vectura Group Announces Phase III Trials for NVA237, QVA149 II-46

Novartis Gets EU Approval for Onbrez® Breezhaler® II-47

Novartis Gets Complete Response Letter for QAB149, from US FDA II-47

Novartis Obtains EU Approval for Xolair® for Treating Severe

Asthma in Children Under 11 Years II-47

AstraZeneca Gets FDA Complete Response Letter for Symbicort

in Paediatric Patients II-47

AstraZeneca Gets FDA Approval for Symbicort in COPD II-48

3M Drug Delivery Systems Unveils 3M Face Seal Valve, 3M

Plasma Coating Technology II-48

Nanotechnology Victoria, Monash University Develops SAW

Generated Mechanism II-48

RTS Life Science Rolls Out Automated Inhaler Testing Solution II-49

Eli Lilly &Co and Alkermes Abandon Inhaled Insulin

Development Deal II-49

Novo-Nordisk Drops Development Plan of Inhaled Insulin II-49

Concomitant Use of Tiotropium, Nebulized Formoterol Fumarate

to Relieve COPD Symptoms II-49

Advair Gets FDA Nod for Advair 250/50 II-50

5. RECENT INDUSTRY ACTIVITY II-51

Dainippon Sumitomo Concludes Acquisition of Sepracor II-51

MicroDose Therapeutx Acquires ViroPharma Investigational

Compounds II-51

Sepracor Grants Non-Exclusive License for XOPENEX® to Teva

and Barr II-51

Skyepharma, Novartis Terminate Formoterol Certihaler Deal II-51

Tidal Air to Sell Matrix Aerosol Delivery System II-51

Battelle Memorial Institute Purchases Assets of Ventaira

Pharmaceuticals Inc II-52

Aptar Pharma to Roll Out Pulmonary & Nasal Devices In India II-52

3M Drug Delivery Systems Unveils New Singaporean Facility II-52

Forest Laboratories, Almirall, Extend Collaboration for

LAS100977 II-52

MicroDose Therapeutx, Merck Expand Collaboration Deal II-52

AstraZeneca Sells API Facility to Minakem II-52

ALR Technologies, Pari Enter Into Agreement II-53

Akela Adds Amendment Into Fentanyl TAIFUN® License Deal with

Teikoku Seiyaku II-53

Novartis, Schering-Plough Revise Collaboration Terms II-53

Astellas, AstraZeneca Ink Co-Promotion Agreement for

Symbicort Turbuhaler II-53

Iroko Cardio Inks Distribution Agreement with Chiesi

Farmaceutici II-53

Novartis Completes Acquisition of Nektar's Pulmonary Business II-54

3M, Cambridge Consultants Forge Licensing Deal for DPI

Technology II-54

Savara Relocates Headquarters to Texas II-54

GSK to Take Over Genelabs Technologies Inc II-54

Novo Nordisk Hand Over Inhaled Insulin Patents to Aradigm II-55

Sepracor Enters Into Agreement with Arrow International II-55

Royal Philips Electronics Acquires Medel, Melhk II-55

Aerogen Concludes Management Buyout from Nektar II-55

Valois Pharma Bags Multi Million Contract II-56

6. FOCUS ON SELECT PLAYERS II-57

3M Drug Delivery Systems Division (USA) II-57

Akela Pharma Inc (Canada) II-57

Alkermes, Inc. (USA) II-57

Aradigm Corporation (USA) II-58

AstraZeneca Plc (UK) II-58

Baxter International Inc. (USA) II-58

Chiesi Farmaceutici SpA (Italy) II-59

Consort Medical Plc (UK) II-60

Dey Pharma L.P. (USA) II-60

GlaxoSmithKline Plc (UK) II-61

Graceway Pharmaceuticals, LLC (USA) II-61

NovartiS AG (Switzerland) II-61

Oriel Therapeutics, Inc. (USA) II-62

Sepracor, Inc. (USA) II-62

SkyePharma Plc (UK) II-62

Valois S.A.S. (France) II-63

Vectura Group Plc (UK) II-63

7. GLOBAL MARKET PERSPECTIVE II-64

Table 2: World Recent Past, Current and Future Analysis for

Pulmonary Drug Delivery Technologies by Geographic Region -

US, Canada, Japan, Europe, Asia Pacific (excluding Japan),

Latin America and Rest of the World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) II-64

Table 3: World Historic Review for Pulmonary Drug Delivery

Technologies by Geographic Region - US, Canada, Japan,

Europe, Asia Pacific (excluding Japan), Latin America and Rest

of the World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) II-65

Table 4: World 13-Year Perspective for Pulmonary Drug Delivery

Technologies by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia Pacific

(excluding Japan), Latin America and Rest of the World Markets

for Years 2003, 2009, and 2015 (includes corresponding

Graph/Chart) II-66

By Product Segments II-67

Table 5: World Recent Past, Current and Future Analysis for

Metered Dosage Inhalers (MDIs) by Geographic Region - US,

Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin

America and Rest of the World Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) II-67

Table 6: World Historic Review for Metered Dosage Inhalers

(MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia

Pacific (excluding Japan), Latin America and Rest of the World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) II-68

Table 7: World 13-Year Perspective for Metered Dosage

Inhalers (MDIs) by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia Pacific

(excluding Japan), Latin America and Rest of the World Markets

for Years 2003, 2009, and 2015 (includes corresponding

Graph/Chart) II-69

Table 8: World Recent Past, Current and Future Analysis for

Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada,

Japan, Europe, Asia Pacific (excluding Japan), Latin America

and Rest of the World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015(includes corresponding Graph/Chart) II-70

Table 9: World Historic Review for Dry Powder Inhalers (DPIs)

by Geographic Region - US, Canada, Japan, Europe, Asia Pacific

(excluding Japan), Latin America and Rest of the World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) II-71

Table 10: World 13-Year Perspective for Dry Powder Inhalers

(DPIs) by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia Pacific (excluding

Japan), Latin America and Rest of the World Markets for Years

2003, 2009, and 2015 (includes corresponding Graph/Chart) II-72

Table 11: World Recent Past, Current and Future Analysis for

Other Pulmonary Drug Delivery Technologies by Geographic

Region - US, Canada, Japan, Europe, Asia Pacific (excluding

Japan), Latin America and Rest of the World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) II-73

Table 12: World Historic Review for Other Pulmonary Drug

Delivery Technologies by Geographic Region - US, Canada,

Japan, Europe, Asia Pacific (excluding Japan), Latin America

and Rest of the World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-74

Table 13: World 13-Year Perspective for Other Pulmonary Drug

Delivery Technologies by Geographic Region - Percentage

Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia

Pacific (excluding Japan), Latin America and Rest of the World

Markets for Years 2003, 2009, and 2015 (includes corresponding

Graph/Chart) II-75

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Current Market Scenario III-1

Major Growth Areas/Indicators III-1

Respiratory Diseases III-1

Cancer III-2

Cystic Fibrosis III-2

HFA Albuterol Eats into CFC Inhalers Market III-2

Table 14: US Albuterol Inhalers Market in Aerosol Beta

Agonists Category (2006 & 2007): Percentage Share Breakdown

of Revenue by Product Type (includes corresponding

Graph/Chart) III-3

New & Popular DPIs in the US III-3

Nebulizers: Displaying Promising Growth III-3

Table 15: US Nebulizers Market (2008): Percentage Share

Breakdown of Revenues by Segment (includes corresponding

Graph/Chart) III-4

Role of FDA III-4

Key Market Share Findings III-4

Table 16: US Bronchodilators Market (2006): Percentage

Share Breakdown of Revenues by Key Players (includes

corresponding Graph/Chart) III-4

Table 17: US Anti-Inflammatory Market (2006): Percentage

Share Breakdown of Revenues by Key Players (includes

corresponding Graph/Chart) III-5

Table 18: US Bronchodilators Market (2009): Percentage

Share Breakdown of Revenues by Segment (includes

corresponding Graph/Chart) III-5

Table 19: US Anti-Inflammatory Market (2006): Percentage

Share Breakdown of Revenues by Segment (includes

corresponding Graph/Chart) III-5

Product Launches/Developments III-5

Strategic Corporate Developments III-8

Select Players III-11

B.Market Analytics III-14

Table 20: US Recent Past, Current and Future Analysis for

Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and

Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-14

Table 21: US Historic Review for Pulmonary Drug Delivery

Technologies by Product Segment - Metered Dose Inhalers

(MDIs), Dry Powder Inhalers (DPIs) and Other Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-15

Table 22: US 13-Year Perspective for Pulmonary Drug Delivery

Technologies by Product Segment - Percentage Breakdown of

Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder

Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015

(includes corresponding Graph/Chart) III-15

2. CANADA III-16

A.Market Analysis III-16

Outlook III-16

Product Launch III-16

Strategic Corporate Developments III-16

Akela Pharma Inc - A Key Canadian Player III-16

B.Market Analytics III-17

Table 23: Canadian Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-17

Table 24: Canadian Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-18

Table 25: Canadian 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-18

3. JAPAN III-19

A.Market Analysis III-19

Outlook III-19

Product Launch III-19

Strategic Corporate Development III-19

B.Market Analytics III-20

Table 26: Japanese Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-20

Table 27: Japanese Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-21

Table 28: Japanese 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-21

4. EUROPE III-22

A.Market Analysis III-22

Outlook III-22

Growth Drivers III-22

Table 29: European Drug Delivery Market: Number of Deals

Between Pharmaceutical/ Biotechnology Companies and Drug

Delivery Companies for 2004 & 2007 III-23

Focus of R&D Shifts to Diabetes Treatment III-23

Table 30: Research Activity Distribution in the European

Pulmonary Drug Delivery Market (2007): Percentage Share

Breakdown of Activity by Therapeutic Area (includes

corresponding Graph/Chart) III-23

European Pulmonary Drug Delivery Market: Drugs In

Clinical Pipeline As of 2007 III-24

DPIs in Europe III-24

Product Launches/Developments III-25

Strategic Corporate Developments III-26

Novartis Ag (Switzerland) - A Key European Player III-27

B.Market Analytics III-28

Table 31: European Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Geographic

Region - France, Germany, Italy, UK, Spain, Russia and Rest

of Europe Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-28

Table 32: European Historic Review for Pulmonary Drug

Delivery Technologies by Geographic Region - France,

Germany, Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-29

Table 33: European 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Geographic Region - Percentage

Breakdown of Dollar Sales for France, Germany, Italy, UK,

Spain, Russia and Rest of Europe Markets for Years 2003,

2009 and 2015 (includes corresponding Graph/Chart) III-30

Table 34: European Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-31

Table 35: European Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-32

Table 36: European 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-33

4a. FRANCE III-34

A.Market Analysis III-34

Outlook III-34

Strategic Corporate Development III-34

Valois S.A.S. - A Key Player III-34

B.Market Analytics III-35

Table 37: French Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-35

Table 38: French Historic Review for Pulmonary Drug Delivery

Technologies by Product Segment - Metered Dose Inhalers

(MDIs), Dry Powder Inhalers (DPIs) and Other Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-36

Table 39: French 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-36

4b. GERMANY III-37

Market Analysis III-37

Table 40: German Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-37

Table 41: German Historic Review for Pulmonary Drug Delivery

Technologies by Product Segment - Metered Dose Inhalers

(MDIs), Dry Powder Inhalers (DPIs) and Other Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-38

Table 42: German 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-38

4c. ITALY III-39

A.Market Analysis III-39

Outlook III-39

Chiesi Farmaceutici SpA - A Key Player III-39

B.Market Analytics III-40

Table 43: Italian Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-40

Table 44: Italian Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-41

Table 45: Italian 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-41

4d. THE UNITED KINGDOM III-42

A.Market Analysis III-42

Outlook III-42

Market Overview III-42

Areas of Growth III-42

Progress in Drug Delivery III-42

Product Launches/Developments III-43

Strategic Corporate Developments III-44

Select Players III-44

B.Market Analytics III-47

Table 46: UK Recent Past, Current and Future Analysis for

Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and

Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-47

Table 47: UK Historic Review for Pulmonary Drug Delivery

Technologies by Product Segment - Metered Dose Inhalers

(MDIs), Dry Powder Inhalers (DPIs) and Other Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) III-48

Table 48: UK 13-Year Perspective for Pulmonary Drug Delivery

Technologies by Product Segment - Percentage Breakdown of

Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder

Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015

(includes corresponding Graph/Chart) III-48

4e. SPAIN III-49

Market Analysis III-49

Table 49: Spanish Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-49

Table 50: Spanish Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-50

Table 51: Spanish 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-50

4f. RUSSIA III-51

Market Analysis III-51

Table 52: Russian Recent Past, Current and Future Analysis

for Pulmonary Drug Delivery Technologies by Product Segment -

Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)

and Other Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-51

Table 53: Russian Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-52

Table 54: Russian 13-Year Perspective for Pulmonary Drug

Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-52

4g. REST OF EUROPE III-53

Market Analysis III-53

Table 55: Rest of Europe Recent Past, Current and Future

Analysis for Pulmonary Drug Delivery Technologies by Product

Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers

(DPIs) and Other Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-53

Table 56: Rest of Europe Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-54

Table 57: Rest of Europe 13-Year Perspective for Pulmonary

Drug Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-55

5. ASIA-PACIFIC III-56

A.Market Analysis III-56

Outlook III-56

Regional Snapshot III-56

India III-56

Nebulizers Market in India: A Quick Primer III-56

Dry Powder Inhalers for Children III-56

Product Launch III-56

Strategic Corporate Developments III-57

B.Market Analytics III-58

Table 58: Asia-Pacific Recent Past, Current and Future

Analysis for Pulmonary Drug Delivery Technologies by Product

Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers

(DPIs) and Other Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-58

Table 59: Asia-Pacific Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-59

Table 60: Asia-Pacific 13-Year Perspective for Pulmonary

Drug Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-60

6. LATIN AMERICA III-61

Market Analysis III-61

Table 61: Latin American Recent Past, Current and Future

Analysis for Pulmonary Drug Delivery Technologies by Product

Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers

(DPIs) and Other Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-61

Table 62: Latin American Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-62

Table 63: Latin American 13-Year Perspective for Pulmonary

Drug Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-63

7. REST OF WORLD III-64

Market Analysis III-64

Table 64: Rest of World Recent Past, Current and Future

Analysis for Pulmonary Drug Delivery Technologies by Product

Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers

(DPIs) and Other Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) III-64

Table 65: Rest of World Historic Review for Pulmonary Drug

Delivery Technologies by Product Segment - Metered Dose

Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) III-65

Table 66: Rest of World 13-Year Perspective for Pulmonary

Drug Delivery Technologies by Product Segment - Percentage

Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),

Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009

and 2015 (includes corresponding Graph/Chart) III-66

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 61 (including Divisions/Subsidiaries - 75)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 36

Canada 4

Japan 4

Europe 30

France 1

Germany 7

The United Kingdom 7

Italy 1

Spain 2

Rest of Europe 12

Middle East 1

------------------------------------------

To order this report:

Medical Equipment and Supply Industry: Global Pulmonary Drug Delivery Technologies industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Global HIV Drugs industry
2. Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets
3. Reportlinker Adds Antifungal Drugs: Technologies and Global Markets
4. Reportlinker Adds The World Anesthesia Drug Market
5. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
6. Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025
7. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
8. Reportlinker Adds Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
9. Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey)
10. Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
11. Reportlinker Adds World Wound Management Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... an agreement to acquire a majority ownership interest in ... equipment in Brazil . ... Blumenau, Brazil, Dental Cremer is the dental distribution business of ...
(Date:2/5/2016)... 4, 2016 France , ... , UK, and Israel ). It includes a 10-year ... 3 GD, segmented by age and sex in these markets. GD epidemiology ... Report is in-depth, high quality, transparent and market-driven, providing expert analysis of ... Germany , Italy , ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
Breaking Medicine Technology:
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Looking for ... may be at the tips of your toes. Foot massage, whether administered by a ... pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
Breaking Medicine News(10 mins):